Polatuzumab vedotin

维泊妥珠单抗

Report date: 2026/04/03 20:03:44
First In Class

Base Information

Drug NamePolatuzumab vedotin
Drug Alias Name维博妥珠单抗Polatuzumab vedotin-piiqACD79B-VCMMAEPolivy优罗华 +[10] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Cleavable linker > VC linkerBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > MMAE payloadBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionTubulin polymerisation inhibitorsAnti-CD79B
TargetsTubulinB-cell antigen receptor complex-associated protein beta chain
Therapy Area/IndicationsLymphoma, FollicularLymphoma, Large B-Cell, DiffuseLymphoma, B-Cell +[6] 
Global Approved IndicationsLymphoma, Large B-Cell, Diffuse
Approved Indications in ChinaLymphoma, Large B-Cell, Diffuse
Original Approved Country/TerritoryUnited States
Original Approved Date2019/06/10
Country/TerritoryMainland China(BOAO LECHENG)CzechiaBelgium +[26] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesSeagen IncGenentech Inc
China Registration ClassN/A

Develop Information

Active CompaniesF. Hoffmann-La Roche AgF. Hoffmann-La Roche LtdGenentech Inc +[6] 
Inactive CompaniesRoche Pharma (Schweiz) AgUniversity Of Colorado Denver
Active IndicationsLymphoma, FollicularLymphoma, Large B-Cell, DiffuseLymphoma, B-Cell +[5] 
Inactive IndicationsLeukemia, Lymphocytic, Chronic, B-Cell

Other Information

ATC CodeL01XC
Related LinksWikipediaDrugBankKEGG